Clinical Benefit of Adjunctive Rituximab in Anti–Interferon-Gamma Autoantibody-Associated Immunodeficiency: A Retrospective Self-Controlled Cohort Study
Open Access
- 30 October 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Abstract
Background: Antimicrobial therapy is the cornerstone of treatment for anti–interferon-gamma (IFN-γ) autoantibody-associated immunodeficiency (AOID), but persistent or relapsing infections remain challenging. We evaluated outcomes associated with adjunctive rituximab in patients with AOID. Methods: We conducted a retrospective self-controlled cohort study of adult patients with AOID treated at a tertiary care hospital in Northern Thailand between January 2019 and December 2024. Each patient contributed data from 2 treatment periods: antimicrobial therapy alone and with adjunctive rituximab. Clinical and laboratory outcomes were compared over 3-month observation windows. Results: Among 14 patients with AOID, the mean age was 61.00 ± 8.84 years, and 6 patients (42.86%) were male. Nontuberculous mycobacteria (NTM) infection was present in all patients. Rapidly growing mycobacteria infections were the predominant NTM infections in both treatment periods, occurring in 13 patients (92.86%). Compared with the antimicrobial-only period, adjunctive rituximab was associated with a significantly higher likelihood of successful antimicrobial de-escalation (adjusted odds ratio, 5.38; 95% confidence interval [CI], 1.16–25.00; P = .032). Rituximab exposure was also associated with a greater reduction in absolute lymphocyte count (adjusted β, −379 cells/µL; 95% CI, −725 to −33; P = .032) and a modest increase in alkaline phosphatase (adjusted β, 32.8 U/L; 95% CI, 8.7–56.9; P = .008). No rituximab-associated infusion reactions, hypersensitivity reactions, severe infections related to immunosuppression, or deaths were observed. Conclusions: Adjunctive rituximab was associated with a higher likelihood of successful antimicrobial de-escalation without major short-term safety concerns. Further prospective evaluation is warranted.Keywords
This publication has 19 references indexed in Scilit:
- Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti-IFN-γ Immunodeficiency.JAMA Network Open, 2026
- Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency SyndromeClinical Infectious Diseases, 2023
- Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset ImmunodeficiencyJournal of Clinical Immunology, 2023
- Anti-interferon-γ autoantibody-associated immunodeficiencyCurrent Opinion in Immunology, 2021
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineClinical Infectious Diseases, 2020
- Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti–Interferon-γ AutoantibodiesClinical Infectious Diseases, 2020
- Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium avium Infection in a Patient with Anti-Interferon-γ AutoantibodyJournal of Clinical Immunology, 2017
- Identification of a major epitope by anti-interferon-γ autoantibodies in patients with mycobacterial diseaseNature Medicine, 2016
- Persistent Mycobacterium abscessus infection secondary to interferon-γ autoantibodiesAnnals of Allergy, Asthma & Immunology, 2016
- Adult-Onset Immunodeficiency in Thailand and TaiwanNew England Journal of Medicine, 2012